Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Effectiveness of T-DXd Across HER2-positive Solid Tumors in Patients Who Have Received Prior Systemic Treatment and Have no Satisfactory Alternative Treatment Options: A Hybrid Observational Study

NCT07124000 is registered in ClinicalTrials.gov with AstraZeneca as lead sponsor.

NCT NCT07124000
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07124000 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Effectiveness of T-DXd Across HER2-positive Solid Tumors in Patients Who Have Received Prior Systemic Treatment and Have no Satisfactory Alternative Treatment Options: A Hybrid Observational Study
Lead sponsor
AstraZeneca
Phase
Observational
Overall status
Recruiting
Start date
September 18, 2025
Completion date
March 30, 2028
Enrollment
100 (estimated)
Sites
18

Conditions

As the registry lists them; a condition with its own page is linked.

adenocarcinoma (nos), anal cancer, bladder cancer, cervical cancer, endometrial cancer, esophageal cancer, gall bladder cancer, gastrointestinal stromal tumour, head and neck cancer, liver cancer, melanoma, mouth cancer, nasopharangeal cancer, neuroendocrine, gastrointestinal cancer, ovarian cancer, pancreatic cancer, prostate cancer, renal cell carcinoma, salivary gland cancer, sarcoma, small cell lung cancer, testicular cancer, throat cancer, thyroid cancer, urethral cancer, vaginal cancer, vulvar cancer